Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
ANN ARBOR, Mich., Dec. 22, 2020 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
-
ANN ARBOR, Mich., Oct. 23, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
-
Lead candidate ONL1204 advances into Phase I clinical study in retinal detachment in Australia ANN ARBOR, Mich., Oct. 08, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical...
-
ANN ARBOR, Mich., Aug. 22, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
-
ANN ARBOR, Mich., Aug. 22, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients with retinal disease, today...
-
ANN ARBOR, Mich., June 18, 2019 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving vision in a range of retinal diseases, today...
-
ANN ARBOR, MI--(Marketwired - May 17, 2017) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today...
-
ANN ARBOR, MI--(Marketwired - Mar 28, 2017) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today...
-
ANN ARBOR, MI--(Marketwired - Mar 21, 2017) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced...
-
ANN ARBOR, MI--(Marketwired - Feb 11, 2016) - ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for preserving sight in a range of retinal diseases, today announced...